Pediatrics Articles

Pediatrics

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The nation's supply of Hib vaccine should see a much–needed upsurge in the coming weeks, thanks to the Aug. 19 FDA approval of GlaxoSmithKline's Hiberix as a booster dose for children ages 15 months to 4 years. The CDC – in consultation with ACIP, the AAFP and the American Academy of Pediatrics – recommended June 25 that physicians reinstate the Hib booster dose for children ages 12–15 months who have completed the three–dose primary series. A booster dose also should be given to older children (i.e., those as old as 59 months) in whom the booster was deferred during their next routinely scheduled office visit. A nationwide Hib vaccine shortage started in 2007, when Merck & Co. Inc. recalled a dozen lots of Hib–containing vaccine and later suspended production of its Hib–containing vaccine products. Merck said on its Web site Aug. 24 that it anticipates its monovalent Hib vaccine PedvaxHIB will return to the U.S. market by the first quarter of 2010, with the possibility of limited availability in the fourth quarter of 2009. Despite manufacturer Sanofi Pasteur's attempts to fill the Hib vaccine gap with two Hib–containing vaccine products, the CDC began receiving case reports of invasive Hib disease in children last year, leading the agency to remind physicians of the need to complete the primary series using whatever vaccine was available, including combination products.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address